Arecor Limited, the specialty pharmaceutical company leveraging its innovative and proprietary formulation technology to develop superior treatments for a range of disease areas, including diabetes, today announces that a Phase I Clinical Trial Application (“CTA”) for product candidate AT247 has been approved by the Bundesamt für Sicherheit im Gesundheitswesen (BASG), the Austrian Federal Office for Safety in Health Care.
N-Site is a unique knowledge portal which provides expert insight and expertise for organisations, professionals and academics in the life sciences sector. This resource is now free to all subscribers, reflecting our intention for this resource to be used by as many as possible, and offers over 85 Guidance Notes from FTI Consulting, Gill Jennings & Every and Taylor Wessing on the key issues affecting companies in the sector.
Arecor Limited, the specialty pharmaceutical company leveraging its innovative and proprietary formulation technology to develop superior treatments for a range of disease areas, including diabetes, is pleased to announce the appointment of Susan Lowther as Chief Financial Officer. Susan was appointed to the board with effect from 4th March 2019.
Oxford, UK – March 6, 2019 – Blue Earth Diagnostics, a leading molecular imaging diagnostics company, recently celebrated the company’s five year anniversary. During this time, Blue Earth Diagnostics has delivered five years of innovation and continued growth with a proven track record and depth of expertise in the rapid development and global commercialization of radiopharmaceuticals for cancer management. Blue Earth Diagnostics employs over 100 people in Europe and in the USA.